Patents by Inventor Kyeong-Soo Kim

Kyeong-Soo Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220207327
    Abstract: According to the present invention, a distributed convolution processing system in a network environment includes: a plurality of devices and servers connected on a communication network and receiving video signals or audio signals, in which the each device has a convolution means that preprocesses a matrix multiplication and a matrix sum, converts calculated feature map (FM) and convolution network (CNN) structure information, and a weighting parameter (WP) into packets, and transfers the packets to the server, and the server performs comprehensive learning and an inference computation by using the feature map (FM) and the weighting parameter which are convolution calculation results preprocessed in the distributed packets transferred from the each device, and performs learning by repeating and updating a process of transferring each of updated parameters for each neural network to the each device again.
    Type: Application
    Filed: May 28, 2021
    Publication date: June 30, 2022
    Inventors: Kyeong Soo Kim, Sang Hoon Lee
  • Publication number: 20220207356
    Abstract: A neural network processing unit for a device according to the present invention includes an AV input matcher that receives a video signal or audio signal input from the outside; a convolution computation controller which receives and buffers the video signal or audio signal from the AV input matcher, divides the video signal or audio signal into overlapping video segments according to a size of a convolution kernel, and transfers the divided data; a convolution computation array which consists of a plurality of arrays, performs independent convolution computations for each divided video block by receiving the divided data, and transfers the results; an active pass controller which receives feature map (FM) information as convolution computation results from the plurality of convolution computation arrays to transfer the FM information to the convolution computation controller again for subsequent convolution computations or perform activation determination and pooling computation on a neural network structur
    Type: Application
    Filed: May 28, 2021
    Publication date: June 30, 2022
    Inventors: Kyeong Soo KIM, Sang Hoon LEE
  • Patent number: 10983348
    Abstract: A head mount wearable device is provided. The housing includes a first surface and a second surface, in which the first surface faces the face of a user and the second surface is opposite to the first surface when a user wears the head mount wearable device, a pair of lenses disposed inside at least one opening formed through the housing from the first surface to the second surface, at least one mounting member connected to the housing and configured to be worn by a user where the pair of lenses are positioned in front of the eyes of a user, and a holder assembly formed on the second surface or close to the second surface to hold a mobile device including a display and holding the mobile device where the display of the mobile device faces the opening.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: April 20, 2021
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Ji-Seong Hwang, Chung-Keun Yoo, Kyu-Myeong Kang, Kyeong-Soo Kim, Jae-Cheon Kim, Suk-Jin Yun
  • Publication number: 20190064523
    Abstract: A head mount wearable device is provided. The housing includes a first surface and a second surface, in which the first surface faces the face of a user and the second surface is opposite to the first surface when a user wears the head mount wearable device, a pair of lenses disposed inside at least one opening formed through the housing from the first surface to the second surface, at least one mounting member connected to the housing and configured to be worn by a user where the pair of lenses are positioned in front of the eyes of a user, and a holder assembly formed on the second surface or close to the second surface to hold a mobile device including a display and holding the mobile device where the display of the mobile device faces the opening.
    Type: Application
    Filed: July 18, 2018
    Publication date: February 28, 2019
    Inventors: Ji-Seong HWANG, Chung-Keun YOO, Kyu-Myeong KANG, Kyeong-Soo KIM, Jae-Cheon KIM, Suk-Jin YUN
  • Patent number: 9931406
    Abstract: Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: April 3, 2018
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: Yong Il Kim, Kyeong Soo Kim, Jin Cheul Kim, Yo Han Kim, Jae Hyun Park, Jong Soo Woo
  • Publication number: 20170340744
    Abstract: Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time.
    Type: Application
    Filed: August 11, 2017
    Publication date: November 30, 2017
    Applicant: Hanmi Pharm. Co., Ltd.
    Inventors: Yong Il Kim, Kyeong Soo Kim, Jin Cheul Kim, Yo Han Kim, Jae Hyun Park, Jong Soo Woo
  • Patent number: 9731022
    Abstract: Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: August 15, 2017
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: Yong Il Kim, Kyeong Soo Kim, Jin Cheul Kim, Yo Han Kim, Jae Hyun Park, Jong Soo Woo
  • Patent number: 9549936
    Abstract: Disclosed are a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same and a method for preparing the same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: January 24, 2017
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Kyeong Soo Kim, Deokkyu Lee, Dong Ho Kim, Yong II Kim, Jae Hyun Park, Jong Soo Woo
  • Patent number: 9486528
    Abstract: The present invention relates to a pharmaceutical formulation for oral administration for preventing or treating allergic rhinitis or asthma, which comprises: (a) a first particle part comprising levocetirizine or a pharmaceutically acceptable salt thereof and an organic acid; and (b) a second particle part comprising montelukast or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention comprises an organic acid as a stabilizing agent, which can effectively inhibit the production of levocetirizine and montelukast related substances, and thus, show good stability.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: November 8, 2016
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Taek Kwan Kwon, Dong Ho Kim, Kyeong Soo Kim, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Publication number: 20160089339
    Abstract: Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects.
    Type: Application
    Filed: November 6, 2015
    Publication date: March 31, 2016
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Yong II KIM, Dong Ho KIM, Taek Kwan KWON, Kyeong Soo KIM, Jae Hyun PARK, Jong Soo WOO
  • Patent number: 9283232
    Abstract: Provided is a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: March 15, 2016
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Kyeong Soo Kim, Deokkyu Lee, Dong Ho Kim, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Publication number: 20160060310
    Abstract: Protein transduction exploits the ability of some cell-penetrating peptide (CPP) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic CPPs, named membrane translocating sequence (MTS), membrane translocating motif (MTM) and macromolecule transduction domain (MTD), are able to deliver biologically active proteins into a variety of cells and tissues. Various cargo proteins fused to these CPPs have been used to test the functional and/or therapeutic efficacy of protein transduction. For example, recombinant proteins consisting of suppressor of cytokine signaling 3 protein (CP-SOCS3) fused to the fibroblast growth factor (FGF) 4-derived MTM were developed to inhibit inflammation and apoptosis. However, CP-SOCS3 fusion proteins expressed in bacteria were hard to purify in soluble form. To address these critical limitations, CPP sequences called advanced MTDs (aMTD) have been developed in this art.
    Type: Application
    Filed: August 27, 2015
    Publication date: March 3, 2016
    Inventors: Daewoong JO, Young Sil CHOI, Youn Seo HWANG, Kyeong Soo KIM
  • Publication number: 20160045444
    Abstract: Provided is a composite formulation comprising: (i) a core including a first pharmacological component; and (ii) a film coating layer formed on a surface of the core, which contains rosuvastatin or a pharmaceutically acceptable salt thereof as a second pharmacological component and a polyvinyl alcohol-polyethylene glycol graft copolymer and polyvinyl alcohol as a coating material. In the composite formulation of the present invention, tension and fluidity of the film coating layer are excellent, and thus breakage and a defective ratio are low. Accordingly, a composite agent containing rosuvastatin effective to relieve and treat a hyperlipemia symptom, or its pharmaceutically acceptable salt can be provided with high efficiency, and is present in a composite formulation form, and thus compliance of a patient can be improved.
    Type: Application
    Filed: April 30, 2014
    Publication date: February 18, 2016
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Yong Il KIM, Hayoung JEONG, Kyeong Soo KIM, Jae Hyun PARK, Jong Soo WOO
  • Patent number: 9220704
    Abstract: The present invention relates to a hard capsule composite formulation comprising a capsule having a hemispherical closure at each end and an interior space; and one or more tablets encapsulated in the capsule, wherein the tablet or the tablets as a whole have a shape conforming to the internal space of the capsule. The hard capsule composite formulation can efficiently charge pharmaceutical compositions inside the limited interior space of the capsule, and hence, it allows packing a high-dose of pharmaceutical composition in a relatively small-sized capsule, which increases productivity and patient compliance. Also, the composite formulation exhibits good dissolution rate because pharmaceutically active ingredients contained in the capsule are separated from one another, and thus, the ingredients are less affected by the dissolution rate of one another, allowing good storage stability which can optimize the therapeutic effects.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: December 29, 2015
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Kyeong Soo Kim, Ki Young Jang, Seung Jae Park, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Patent number: 9161933
    Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof, which exhibits high dissolution rates of amlodipine and losartan even under a low pH condition and improved storage stability.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: October 20, 2015
    Assignee: HANMI SCIENCE CO., LTD
    Inventors: Jae Hyun Park, Kyeong Soo Kim, Ho Taek Yim
  • Publication number: 20150283151
    Abstract: Disclosed are a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same and a method for preparing the same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.
    Type: Application
    Filed: June 22, 2015
    Publication date: October 8, 2015
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Kyeong Soo KIM, Deokkyu LEE, Dong Ho KIM, Yong II KIM, Jae Hyun PARK, Jong Soo WOO
  • Publication number: 20150157566
    Abstract: Provided is a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.
    Type: Application
    Filed: June 3, 2013
    Publication date: June 11, 2015
    Inventors: Kyeong Soo Kim, Deokkyu Lee, Dong Ho Kim, Yong II Kim, Jae Hyun Park, Jong Soo Woo
  • Publication number: 20150098992
    Abstract: Provided is a composite formulation comprising multi-unit spheroidal tablets (MUSTs) encapsulated in a hard capsule and a method for preparing same. The inventive hard capsule composite formulation can effectively charge the MUSTs in the limited space of the capsule, which allows charging a high dose of different pharmaceutically active ingredients in a capsule with a relatively small size, to thereby increase the productivity and render it readily administered to patients. Also, the capsule has a good dissolution rate because the pharmaceutically active ingredients contained in the capsule are separated from one another; therefore, the dissolution rates of the ingredients are less affected by one another. It may also be possible to maximize the therapeutic effects of the pharmaceutically active ingredients since the composite formulation has good stability.
    Type: Application
    Filed: April 12, 2013
    Publication date: April 9, 2015
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Kyeong Soo Kim, Dong Ho Kim, Taek Kwan Kwon, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Publication number: 20140356422
    Abstract: The present invention relates to a pharmaceutical formulation for oral administration for preventing or treating allergic rhinitis or asthma, which comprises: (a) a first particle part comprising levocetirizine or a pharmaceutically acceptable salt thereof and an organic acid; and (b) a second particle part comprising montelukast or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention comprises an organic acid as a stabilizing agent, which can effectively inhibit the production of levocetirizine and montelukast related substances, and thus, show good stability.
    Type: Application
    Filed: January 4, 2013
    Publication date: December 4, 2014
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Taek Kwan Kwon, Dong Ho Kim, Kyeong Soo Kim, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Patent number: RE49879
    Abstract: A method and an apparatus for supporting a discontinuous reception (DRX) operation in a Node B in a mobile communication system are provided. The method includes defining a second System Frame Number (SFN) where one cycle of a first SFN corresponds to one bit, transmitting information on the second SFN to a User Equipment (UE), determining a second SFN which is used to transmit a paging signal to the UE, determining a first SFN which is used to transmit the paging signal in the determined second SFN, and transmitting the paging signal to the UE at the determined first SFN.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: March 19, 2024
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Sang-Bum Kim, Sung-Ho Choi, Soeng-Hun Kim, Kyeong-In Jeong, Jung-Soo Jung, Chae-Gwon Lim